- Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90)
- Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial responses
- Manageable overall safety profile observed across multiple expansion cohorts
- Company plans to initiate Phase 2 study in mCRPC in 2023M
PAVmed Shareholders As Of January 15, 2024 Will Participate In Distribution Of ~3.3M Shares Of Lucid Common Stock And Also Announces 1-For-15 Reverse Stock Split
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock1-for-15 reverse stock split to be effective as of market open on December 7, 2023NEW
